A prognostic DNA signature for T1T2 node-negative breast cancer patients

Genes Chromosomes and Cancer

Volumn 49, Issue 12, 2010, Pages 1125-1134

  Gravier, Eléonore ^a,b   Pierron, Gaëlle ^a   Vincent Salomon, Anne ^a   Gruel, Nadége ^a   Raynal, Virginie ^a   Savignoni, Alexia ^a   De Rycke, Yann ^a   Pierga, Jean Yves ^a   Lucchesi, Carlo ^a   Reyal, Fabien ^a   Fourquet, Alain ^a   Roman Roman, Sergio ^a   Radvanyi, François ^a   Sastre Garau, Xavier ^a   Asselain, Bernard ^a,b   Delattre, Olivier ^a  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR;

ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CHROMOSOME 2; CHROMOSOME 3; CHROMOSOME 8; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; OUTCOME ASSESSMENT; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 8; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETIC ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT;

EID: 79952198073     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20820     Document Type: Article

References (44)

1. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M. 2007. Integrated profiling of basal and luminal breast cancers. Cancer Res 67:11565-11575.
2. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534-8540.
3. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi G, Symmans WF, Lazar V, Pusztai L. 2009. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441-451.
4. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 57:289-300.
5. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. 2006. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneexpression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040.
6. Bernardino J, Gerbault-Seureau M, Zafrani B, Dericke Y, Boudou E, Magdelenat H, Dutrillaux B. 1998. Homogeneously staining regions in 223 breast carcinomas: Cytogenetic and clinicopathological correlations. Br J Cancer 78:1214-1218.
7. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. 2006. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043-1048.
8. Cervantes M, Glassman AB. 1996. Breast cancer cytogenetics: A review and proposal for clinical application. Ann Clin Lab Sci 26:208-214.
9. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. 2009. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 4:e6693.
10. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. 2006. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10:529-541.
11. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavare S, Brenton JD, Ylstra B, Caldas C. 2007a. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 8:R215.
12. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M, Naderi A, Roberts I, Barbosa-Morais NL, Garcia MJ, Iyer NG, Kranjac T, Robertson JF, Aparicio S, Tavaré S, Ellis I, Brenton JD, Caldas C. 2007b. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26:1959-1970.
13. Cinieri S, Orlando L, Fedele P, Cusmai A, D'Amico M, Rizzo P, Chetri MC. 2007. Adjuvant strategies in breast cancer: New prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Ann Oncol 18(Suppl 6):vi63-vi65.
14. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C. 1997. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res 57:4360-4367.
15. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C. 2000. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60:1077-1083.
16. Dellas A, Torhorst J, Schultheiss E, Mihatsch MJ, Moch H. 2002. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin Cancer Res 8:1210-1216.
17. Elston C, Ellis I. 1991. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410.
18. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Meterissian S, Omeroglu A, Hallett M, Park M. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527.
19. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. 2004. Analysis of array CGH data: From signal ratio to gain and loss of DNA regions. Bioinformatics 20:3413-3422.
20. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY. 2005. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483-487.
21. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. 2009. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033.
22. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SN. 2008. Genomiccomplexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 112:1993-2003.
23. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, Manie E, Brennetot C, Janoueix-Lerosey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delattre O, Aurias A, Radvanyi F, Barillot E. 2006. VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 22: 2066-2073.
24. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS. 2007. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9:R30.
25. Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS. 2008. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215:398- 410.
26. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. 2009. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. 2009.Clin Cancer Res 15:2711-2722.
27. Neuvial P, Hupe P, Brito I, Liva S, Manie E, Brennetot C, Radvanyi F, Aurias A, Barillot E. 2006. Spatial normalization of array-CGH data. BMC Bioinformatics 7:264.
28. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL. 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157- 1167.
29. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher E, Wickerham D, Bryant J, Wolmark N. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826.
30. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. 2002. FHIT: From gene discovery to cancer treatment and prevention. Lancet Oncol 3:748-754.
31. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. 2006. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12:6652-6662.
32. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J. 2003. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63:8861-8868.
33. Reyal F, Van vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. 2008. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10:R93.
34. Roylance R, Gorman P, Papior T, Wan YL, Ives M, Watson JE, Collins C, Wortham N, Langford C, Fiegler H, Carter N, Gillett C, Sasieni P, Pinder S, Hanby A, Tomlinson I. 2006. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 25:6544-6553.
35. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. 2003. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30-R36.
36. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
37. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH 2nd, Etzell J, Waldman FM. 2002. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 33:628-631.
38. Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. 1998. Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma. Jpn J Clin Oncol 28:5-11.
39. van t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
40. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A. 2007. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9:R24.
41. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O. 2008. ESR1 gene amplification in breast cancer: A common phenomenon? Nat Genet 40:809.
42. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. 2005. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 365:671-679.
43. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van deVijver M, Wheeler TM, Hayes, DF. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18.
44. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA. 2009. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res 69:3795-37801.